Please login to the form below

Not currently logged in
Email:
Password:

CGRP inhibitors

This page shows the latest CGRP inhibitors news and features for those working in and with pharma, biotech and healthcare.

Teva wins FDA OK for crucial migraine drug

Teva wins FDA OK for crucial migraine drug

analysts to predict buoyant sales of the CGRP inhibitors. ... the injectable CGRP inhibitors.

Latest news

  • CGRP migraine drugs need prior approval for use, recommends ICER CGRP migraine drugs need prior approval for use, recommends ICER

    CGRP migraine drugs need prior approval for use, recommends ICER. Suggests clinicians should confirm that patients have tried other therapies prior to using CGRP inhibitors. ... The Institute for Clinical and Economic Review (ICER) is recommending that

  • The year of the blockbuster The year of the blockbuster

    Drugs to watch in 2018. Aimovig (erenumab) from Amgen and Novartis:Migraine prevention is about to undergo a transformation with several novel calcitonin gene-related peptide (CGRP) receptor inhibitors likely gaining ... from two similar drugs targeting

  • ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-line ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-line

    An earlier analysis by the organisation, which used a model price of $8, 500 per year, concluded that CGRP inhibitors would be too expensive at that level. ... As migraine is common, “there may be concerns about affordability and access [and] CGRP

  • Novartis, Amgen set low price for first CGRP migraine drug Novartis, Amgen set low price for first CGRP migraine drug

    Novartis, Amgen set low price for first CGRP migraine drug. Aimovig has a list price of $6, 900 per year. ... The premium over older drugs for prevention should be supportable given that some patients have seen their migraines completely disappear with

  • Allergan’s oral migraine drug closer to US filing Allergan’s oral migraine drug closer to US filing

    Allergan has reported additional phase III results for its oral CGRP inhibitor ubrogepant, setting up a regulatory filing in the US next year. ... The CGRP inhibitors offer hope to patients with severe chronic migraine who can't get relief from the

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics